Application of chitosan microspheres for nasal delivery of vaccines

Biotechnology Advances

Volumn 27, Issue 6, 2009, Pages 857-865

  Kang, Mi Lan ^a   Cho, Chong Su ^b   Yoo, Han Sang ^a  

^a KRF Zoonotic Disease Priority Research Institute   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Chitosan microspheres; Delivery systems; Mucosal vaccines; Nasal vaccines

Indexed keywords

ANTIGEN PRESENTING CELLS; CHITOSAN MICROSPHERES; CONTROLLED RELEASE; DELIVERY SYSTEMS; ENZYMATIC DEGRADATION; IMMUNOGENICITY; IMMUNOMODULATORS; MODIFIED CHITOSAN; MUCOCILIARY CLEARANCE; MUCOSAL VACCINES; MUCOUS MEMBRANES; NASAL DELIVERY; NASAL VACCINES; SYNERGISTIC EFFECT; VACCINE DELIVERY SYSTEM;

ANTIGENS; BIODEGRADABLE POLYMERS; BIOPOLYMERS; CHITIN; CHITOSAN; MICROSPHERES;

VACCINES;

CHITOSAN; MICROSPHERE; VACCINE;

ANTIGEN; BIODEGRADATION; COST; ENZYME ACTIVITY; ORAL HEALTH; SYNERGISM; VACCINE;

CHEMISTRY; INTRANASAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, INTRANASAL; CHITOSAN; MICROSPHERES; VACCINES;

EID: 70349976316     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2009.06.007     Document Type: Review

References (91)

1. Ahire V.J., Sawant K.K., Doshi J.B., and Ravetkar S.D. Chitosan microparticles as oral delivery system for tetanus toxoid. Drug Dev Ind Pharm 33 (2007) 1112-1124
2. Alpar H.O., Somavarapu S., Atuah K.N., and Bramwell V.W. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 57 (2005) 411-430
3. Arora P., Sharma S., and Garg S. Permeability issues in nasal drug delivery. Drug Discov Today 7 (2002) 967-975
4. Artursson P., Lindmark T., Davis S.S., and Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 11 (1994) 1358-1361
5. Baudner B.C., Giuliani M.M., Verhoef J.C., Rappuoli R., Junginger H.E., and Giudice G.D. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 21 (2003) 3837-3844
6. Baudner B.C., Verhoef J.C., Giuliani M.M., Peppoloni S., Rappuoli R., Del Giudice G., et al. Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform. J Drug Target 13 (2005) 489-498
7. Bhardwaj R., and Blanchard J. Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407. J Pharm Sci 85 (1996) 915-919
8. Borchard G., Luessen H.L., De Boer A.G., Verhoef J.C., Lehr C.M., and Junginger H.E. The poteltial of mucoadhesive polymers in enhancing intestinal peptide drus absorption. III: Effect of chitosan glutamate and carbomer on epithelial tight junctions in vitro. J Control Release 39 (1996) 131-138
9. Chowdary K.P., and Rao Y.S. Mucoadhesive microspheres for controlled drug delivery. Biol Pharm Bull 27 (2004) 1717-1724
10. Coeshott C.M., Smithson S.L., Verderber E., Samaniego A., Blonder J.M., Rosenthal G.J., et al. Pluronic F127-based systemic vaccine delivery systems. Vaccine 22 (2004) 2396-2405
11. Costantino H.R., Illum L., Brandt G., Johnson P.H., and Quay S.C. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 337 (2007) 1-24
12. Desai M.P., Labhasetwar V., Walter E., Levy R.J., and Amidon G.L. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res 14 (1997) 1568-1573
13. Dodane V., Khan M.A., and Merwin J.R. Effect of chitosan on epithelial permeability and structure. Int J Pharm 182 (1999) 21-32
14. East L., and Isacke C.M. The mannose receptor family. Biochim Biophys Acta 1572 (2002) 364-386
15. Eldridge J.H., Staas J.K., Meulbroek J.A., Tice T.R., and Gilley R.M. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 59 (1991) 2978-2986
16. Engering A.J., Cella M., Fluitsma D.M., Hoefsmit E.C., Lanzavecchia A., and Pieters J. Mannose receptor mediated antigen uptake and presentation in human dendritic cells. Adv Exp Med Biol 417 (1997) 183-187
17. Gavini E., Hegge A.B., Rassu G., Sanna V., Testa C., Pirisino G., et al. Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int J Pharm 307 (2006) 9-15
18. Harris A.S., Nilsson I.M., Wagner Z.G., and Alkner U. Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin. J Pharm Sci 75 (1986) 1085-1088
19. Hashimoto M., Morimoto M., Saimoto H., Shigemasa Y., Yanagie H., Eriguchi M., et al. Gene transfer by DNA/mannosylated chitosan complexes into mouse peritoneal macrophages. Biotechnol Lett 28 (2006) 815-821
20. Hattori Y., Kawakami S., Suzuki S., Yamashita F., and Hashida M. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochem Biophys Res Commun 317 (2004) 992-999
21. Heritage P.L., Underdown B.J., Brook M.A., and McDermott M.R. Oral administration of polymer-grafted starch microparticles activates gut-associated lymphocytes and primes mice for a subsequent systemic antigen challenge. Vaccine 16 (1998) 2010-2017
22. Holmgren J., and Czerkinsky C. Mucosal immunity and vaccines. Nat Med 11 (2005) S45-53
23. Hussain M.A., Koval C.A., Shenvi A.B., and Aungst B.J. An aminoboronic acid derivative inhibits thymopentin metabolism by mucosal membrane aminopeptidases. Life Sci 47 (1990) 227-231
24. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 15 (1998) 1326-1331
25. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., and Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Del Rev 51 (2001) 81-96
26. Illum L., Watts P., Fisher A.N., Hinchcliffe M., Norbury H., Jabbal-Gill I., et al. Intranasal delivery of morphine. J Pharmacol Exp Ther 301 (2002) 391-400
27. Jabbal-Gill I., Fisher A.N., Rappuoli R., Davis S.S., and Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 16 (1998) 2039-2046
28. Jain S., Singh P., Mishra V., and Vyas S.P. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against Hepatitis B. Immunol Lett 101 (2005) 41-49
29. Jain S.K., Chourasia M.K., Jain A.K., Jain R.K., and Shrivastava A.K. Development and characterization of mucoadhesive microspheres bearing salbutamol for nasal delivery. Drug Deliv 11 (2004) 113-122
30. Jeong K.I., Suzuki H., Nakayama H., and Doi K. Ultrastructural study on the follicle-associated epithelium of nasal-associated lymphoid tissue in specific pathogen-free (SPF) and conventional environment-adapted (SPF-CV) rats. J Anat 196 Pt 3 (2000) 443-451
31. Jiang H.L., Kang M.L., Quan J.S., Kang S.G., Akaike T., Yoo H.S., et al. The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials 29 (2008) 1931-1939
32. Kang M.L., Jiang H.L., Kang S.G., Guo D.D., Lee D.Y., Cho C.S., et al. Pluronic F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. Vaccine 25 (2007) 4602-4610
33. Kang M.L., Kang S.G., Jiang H.L., Guo D.D., Lee D.Y., Rayamahji N., et al. Chitosan microspheres containing Bordetella bronchiseptica antigens as novel vaccine against atrophic rhinitis in pigs. J Microbiol Biotechnol 18 (2008) 1179-1185
34. Kang M.L., Kang S.G., Jiang H.L., Shin S.W., Lee D.Y., Ahn J.M., et al. In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT. Eur J Pharm Biopharm 63 (2006) 215-220
35. Kawakami S., Sato A., Nishikawa M., Yamashita F., and Hashida M. Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes. Gene Ther 7 (2000) 292-299
36. Khatri K., Goyal A.K., Gupta P.N., Mishra N., and Vyas S.P. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int J Pharm 354 (2008) 235-241
37. Kim B., Bowersock T., Griebel P., Kidane A., Babiuk L.A., Sanchez M., et al. Mucosal immune responses following oral immunization with rotavirus antigens encapsulated in alginate microspheres. J Control Release 85 (2002) 191-202
38. Kim T.H., Jin H., Kim H.W., Cho M.H., and Cho C.S. Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells. Mol Cancer Ther 5 (2006) 1723-1732
39. Krauland A.H., Guggi D., and Bernkop-Schnurch A. Thiolated chitosan microparticles: a vehicle for nasal peptide drug delivery. Int J Pharm 307 (2006) 270-277
40. Kumar M., Behera A.K., Lockey R.F., Zhang J., Bhullar G., De La Cruz C.P., et al. Intranasal gene transfer by chitosan DNA nanospheres protects Balb/c mice against acute respiratory syncytial virus infection. Hum Gene Ther 13 (2002) 1415-1425
41. Kunisawa J., Okudaira A., Tsutusmi Y., Takahashi I., Nakanishi T., Kiyono H., et al. Characterization of mucoadhesive microspheres for the induction of mucosal and systemic immune responses. Vaccine 19 (2000) 589-594
42. Kuper C.F., Koornstra P.J., Hameleers D.M., Biewenga J., Spit B.J., Duijvestijn A.M., et al. The role of nasopharyngeal lymphoid tissue. Immunol Today 13 (1992) 219-224
43. Kurono Y., Suzuki M., Mogi G., Yamamoto M., Fujihashi K., McGhee J.R., et al. Effects of intranasal immunization on protective immunity against otitis media. Int J Pediatr Otorhinolaryngol 49 Suppl 1 (1999) S227-S229
44. Kyd J.M., Foxwell A.R., and Cripps A.W. Mucosal immunity in the lung and upper airway. Vaccine 19 (2001) 2527-2533
45. Langermann S., Palaszynski S., Sadziene A., Stover C.K., and Koenig S. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature 372 (1994) 552-555
46. Lee V.H.L., and Yamamoto A. Penetration and enzymatic barriers of peptide and protein absorption. Adv Drug Del Rev 4 (1990) 171-207
47. Lim S.T., Forbes B., Martin G.P., and Brown M.B. In vivo and in vitro characterization of novel microparticulates based on hyaluronan and chitosan hydroglutamate. AAPS PharmSciTech 2 (2001) 20
48. Luessen H.L., de Leeuw B.J., Langemeyer M.W., de Boer A.B., Verhoef J.C., and Junginger H.E. Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm Res 13 (1996) 1668-1672
49. Marttin E., Schipper N.G., Verhoef J.C., and Merkus F.W. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 29 (1998) 13-38
50. McNeela E.A., O'Connor D., Jabbal-Gill I., Illum L., Davis S.S., Pizza M., et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19 (2000) 1188-1198
51. Mitchell D.A., Fadden A.J., and Drickamer K. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR subunit organization and binding to multivalent ligands. J Biol Chem 276 (2001) 28939-28945
52. Miyazaki S., Tobiyama T., Takada M., and Attwood D. Percutaneous absorption of indomethacin from pluronic F127 gels in rats. J Pharm Pharmacol 47 (1995) 455-457
53. Mora A.L., and Tam J.P. Controlled lipidation and encapsulation of peptides as a useful approach to mucosal immunizations. J Immunol 161 (1998) 3616-3623
54. Morikawa K., Okada F., Hosokawa M., and Kobayashi H. Enhancement of therapeutic effects of recombinant interleukin 2 on a transplantable rat fibrosarcoma by the use of a sustained release vehicle, pluronic gel. Cancer Res 47 (1987) 37-41
55. Muller C.P., Beauverger P., Schneider F., Jung G., and Brons N.H. Cholera toxin B stimulates systemic neutralizing antibodies after intranasal co-immunization with measles virus. J Gen Virol 76 Pt 6 (1995) 1371-1380
56. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350 (2004) 896-903
57. Neutra M.R., and Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6 (2006) 148-158
58. O'Hagan D.T., Jeffery H., and Davis S.S. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 11 (1993) 965-969
59. O'Hagan D.T., Rafferty D., Wharton S., and Illum L. Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. Vaccine 11 (1993) 660-664
60. Pereswetoff-Morath L. Microspheres as nasal drug delivery systems. Adv Drug Deliv Rev 29 (1998) 185-194
61. Porporatto C., Bianco I.D., Riera C.M., and Correa S.G. Chitosan induces different L-arginine metabolic pathways in resting and inflammatory macrophages. Biochem Biophys Res Commun 304 (2003) 266-272
62. Rokhade A.P., Shelke N.B., Patil S.A., and Aminabhavi T.M. Novel hydrogel microspheres of chitosan and pluronic F-127 for controlled release of 5-fluorouracil. J Microencapsul 24 (2007) 274-288
63. Rudin A., Johansson E.L., Bergquist C., and Holmgren J. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun 66 (1998) 3390-3396
64. Rydell N., and Sjoholm I. Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant. Vaccine 22 (2004) 1265-1274
65. Sajadi Tabassi S.A., Tafaghodi M., and Jaafari M.R. Induction of high antitoxin titers against tetanus toxoid in rabbits by intranasal immunization with dextran microspheres. Int J Pharm 360 (2008) 12-17
66. Sallusto F., Cella M., Danieli C., and Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182 (1995) 389-400
67. Sankar C., Rani M., Srivastava A.K., and Mishra B. Chitosan based pentazocine microspheres for intranasal systemic delivery: development and biopharmaceutical evaluation. Pharmazie 56 (2001) 223-226
68. Sarkar M.A. Drug metabolism in the nasal mucosa. Pharm Res 9 (1992) 1-9
69. Schipper N.G., Varum K.M., and Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm Res 13 (1996) 1686-1692
70. Schipper N.G., Verhoef J.C., and Merkus F.W. The nasal mucociliary clearance: relevance to nasal drug delivery. Pharm Res 8 (1991) 807-814
71. Schmolka I.R. A comparison of block copolymer surfactant gels. J Am Oil Chem Soc 68 (1997) 206-209
72. Seferian P.G., and Martinez M.L. Immune stimulating activity of two new chitosan containing adjuvant formulations. Vaccine 19 (2000) 661-668
73. Singh M., Briones M., and O'Hagan D.T. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release 70 (2001) 267-276
74. Soane R.J., Frier M., Perkins A.C., Jones N.S., Davis S.S., and Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 178 (1999) 55-65
75. Soane R.J., Hinchcliffe M., Davis S.S., and Illum L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 217 (2001) 183-191
76. Suckow M.A., Jarvinen L.Z., HogenEsch H., Park K., and Bowersock T.L. Immunization of rabbits against a bacterial pathogen with an alginate microparticle vaccine. J Control Release 85 (2002) 227-235
77. Tafaghodi M., Sajadi Tabassi S.A., and Jaafari M.R. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int J Pharm 319 (2006) 37-43
78. Tan M.C., Mommaas A.M., Drijfhout J.W., Jordens R., Onderwater J.J., Verwoerd D., et al. Mannose receptor-mediated uptake of antigens strongly enahnces HLA class II-restricted antigen presentation by cultured dendritic cells. Eur J Immunol 27 (1997) 2426-2435
79. Tian J., Yu J., and Sun X. Chitosan microspheres as candidate plasmid vaccine carrier for oral immunisation of Japanese flounder (Paralichthys olivaceus). Vet Immunol Immunopathol 126 (2008) 220-229
80. Ueno H., Mori T., and Fujinaga T. Topical formulations and wound healing applications of chitosan. Adv Drug Deliv Rev 52 (2001) 105-115
81. Ugwoke M.I., Verbeke N., and Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 53 (2001) 3-21
82. van der Lubben I.M., Kersten G., Fretz M.M., Beuvery C., Coos Verhoef J., and Junginger H.E. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21 (2003) 1400-1408
83. van Der Lubben I.M., Konings F.A., Borchard G., Verhoef J.C., and Junginger H.E. In vivo uptake of chitosan microparticles by murine Peyer's patches: visualization studies using confocal laser scanning microscopy and immunohistochemistry. J Drug Target 9 (2001) 39-47
84. Varshosaz J., Sadrai H., and Alinagari R. Nasal delivery of insulin using chitosan microspheres. J Microencapsul 21 (2004) 761-774
85. Veyries M.L., Couarraze G., Geiger S., Agnely F., Massias L., Kunzli B., et al. Controlled release of vancomycin from poloxamer 407 gels. Int J Pharm 192 (1999) 183-193
86. Wang P.L., and Johnston T.P. Enhanced stability of two model proteins in an agitated solution environment using poloxamer 407. J Parenter Sci Technol 47 (1993) 183-189
87. Westerink M.A., Smithson S.L., Srivastava N., Blonder J., Coeshott C., and Rosenthal G.J. ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine 20 (2001) 711-723
88. Wikingsson L., and Sjoholm I. Polyacryl starch microparticles as adjuvant in oral immunisation, inducing mucosal and systemic immune responses in mice. Vaccine 20 (2002) 3355-3363
89. Xie Y., Zhou N.J., Gong Y.F., Zhou X.J., Chen J., Hu S.J., et al. Th immune response induced by H. pylori vaccine with chitosan as adjuvant and its relation to immune protection. World J Gastroenterol 13 (2007) 1547-1553
90. Zhang L., Parsons D.L., Navarre C., and Kompella U.B. Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release 85 (2002) 73-81
91. Zhou X., Liu B., Yu X., Zha X., Zhang X., Chen Y., et al. Controlled release of PEI/DNA complexes from mannose-bearing chitosan microspheres as a potent delivery system to enhance immune response to HBV DNA vaccine. J Control Release 121 (2007) 200-207